The field of cannabinoid research is advancing, with new discoveries being made about the potential therapeutic benefits of these compounds. However, for these discoveries to be translated into effective treatments for patients, it is essential that proper due diligence is done, and well-designed clinical trials programs are initiated.
In this presentation from the recent International Cannabis Business Conference in Berlin, Terry O’Regan, President of Brains Bioceutical, discusses the course, challenges, considerations, and rewards for advancing the cannabinoid scientific research landscape.
Please wait while you are redirected to the right page...
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.